Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX)
Burchert A et al. Leukemia, January 2026 (epub ahead of print) – open access publication
Link to full abstract